Sukesh Chandran Nair

Sukesh Chandran Nair

Auto-generated profile, based on publicly available information

Sukesh Chandran Nair

Department of Transfusion Medicine and Immunohematology, Christian Medical College, Vellore, India

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2021 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
PDF file
SKSteve Kitchen
Steve Kitchen
DADorothy M. Adcock
Dorothy M. Adcock
RDRay Dauer
Ray Dauer
AKAnn‐Helen Kristoffersen
Ann‐Helen Kristoffersen
Giuseppe LippiGiuseppe Lippi
Giuseppe Lippi
SNSukesh Nair
Sukesh Nair
This guidance document has been prepared on behalf of the International Council for Standardization in Haematology (ICSH). The aim of the document is to provide guidance and recommendations for the processing of citrated blood samples for coagulation tests in clinical laboratories in all regions of the world. The following areas are included in this document: Sample transport including use of pneumatic tubes systems; clots in citrated samples; centrifugation; primary tube storage and stability; interfering substances including haemolysis, icterus and lipaemia; secondary aliquots—transport, storage and processing; preanalytical variables for platelet function testing. The following areas are excluded from this document, but are included in an associated ICSH document addressing collection of samples for coagulation tests in clinical laboratories; ordering tests; sample collection tube and anticoagulant; preparation of the patient; sample collection device; venous stasis before sample collection; order of draw when different sample types are collected; sample labelling; blood‐to‐anticoagulant ratio (tube filling); influence of haematocrit. The recommendations are based on published data in peer‐reviewed literature and expert opinion.

16 July 2020 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
PDF file
IMIan Mackie
Ian Mackie
Ilaria ManciniIlaria Mancini
Ilaria Mancini
JMJoshua Muia
Joshua Muia
JHJohanna Kremer Hovinga
Johanna Kremer Hovinga
SNSukesh Nair
Sukesh Nair
RBRoss Baker
Ross Baker
This guidance document was prepared on behalf of the International Council for Standardization in Haematology (ICSH), by the ADAMTS13 Assay Working Group, which comprises an international group of both clinical and laboratory experts. The document provides recommendations on best practice for the performance of ADAMTS13 assays in clinical laboratories. ADAMTS13 assays support the differential diagnosis of thrombotic microangiopathies and have utility in the management of thrombotic thrombocytopenic purpura (TTP). There are three types of assay: activity, antigen and autoantibody/inhibitor assays. Methods for activity assays differ in terms of sensitivity, specificity, precision and turnaround time. The most widely used assays involve VWF peptide substrates and either chromogenic ELISA or FRET techniques, although chemiluminescence assays and rapid screening tests have recently become available. Tests for autoantibodies and inhibitors allow confirmation of acquired, immune‐mediated TTP, while antigen assays may be useful in congenital TTP and as prognostic markers. In this document, we have attempted to describe ADAMTS13 assays and the conditions that affect them, as well as: blood collection, sample processing, quality control, standardization and clinical utility; recognizing that laboratories in different parts of the world have varying levels of sophistication. The recommendations are based on expert opinion, published literature and good clinical laboratory practice.

7 June 2021 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
PDF file
SKSteve Kitchen
Steve Kitchen
DADorothy M. Adcock
Dorothy M. Adcock
RDRay Dauer
Ray Dauer
AKAnn‐Helen Kristoffersen
Ann‐Helen Kristoffersen
Giuseppe LippiGiuseppe Lippi
Giuseppe Lippi
SNSukesh Nair
Sukesh Nair
This guidance document has been prepared on behalf of the International Council for Standardisation in Haematology (ICSH). The aim of the document is to provide guidance and recommendations for collection of blood samples for coagulation tests in clinical laboratories throughout the world. The following processes will be covered: ordering tests, sample collection tube and anticoagulant, patient preparation, sample collection device, venous stasis before sample collection, order of draw when different sample types need to be collected, sample labelling, blood‐to‐anticoagulant ratio (tube filling) and influence of haematocrit. The following areas are excluded from this document, but are included in an associated ICSH document addressing processing of samples for coagulation tests in clinical laboratories: sample transport and primary tube sample stability; centrifugation; interfering substances including haemolysis, icterus and lipaemia; secondary aliquots—transport and storage; and preanalytical variables for platelet function testing. The recommendations are based on published data in peer‐reviewed literature and expert opinion.

1 June 2002 in The American Journal of Medicine
Verified
Journal Article
Closed access
HNHarris Vezhappilly Kunjali Naina
Harris Vezhappilly Kunjali Naina
SNSukesh C Nair
Sukesh C Nair
DDDolly Daniel
Dolly Daniel
BGBiju George
Biju George
MCMammen Chandy
Mammen Chandy

1 October 2016 in Journal of Clinical Orthopaedics and Trauma
Verified
Journal Article
Closed access
APApurve Parameswaran
Apurve Parameswaran
VKVignesh P. Krishnamoorthy
Vignesh P. Krishnamoorthy
AOAnil T. Oommen
Anil T. Oommen
AJAnita Jasper
Anita Jasper
RKRavi J. Korula
Ravi J. Korula
PPPradeep M. Poonnoose
Pradeep M. Poonnoose

1 November 2009 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
VMVikram Mathews
Vikram Mathews
SNSukesh C Nair
Sukesh C Nair
SDSachin David
Sachin David
AVAuro Viswabandya
Auro Viswabandya
ASAlok Srivastava
Alok Srivastava
Data are limited on inhibitors in people with hemophilia (PWH) in developing countries. There is a perception that the overall prevalence of inhibitors, ranging from 7 to 19% in different reports, may be lower in these countries as compared with that reported from developed countries. This is possible given the fact that most patients are treated after 2 years of age with plasma-derived clotting factor concentrates. Whether genetic or other environmental factors also contribute to this needs further evaluation. There is a need to develop laboratory infrastructure and establish quality control programs for laboratory tests for inhibitors in developing countries. Management options vary widely given the socioeconomic diversity among these countries. Significant individualization of approach to management is therefore required depending on the available resources, particularly with regard to the use of bypassing agents. The limited data on immune tolerance induction with some low-dose regimens deserve further evaluation. Even in resource-constrained environments, education and a policy of systematic screening of patients associated with judicious use of bypassing agents can significantly improve the care of PWH who develop inhibitors.